The global high-affinity nerve growth factor receptor market is anticipated to grow at a significant CAGR of 5.4% during the forecast period 2022-2028. The major factor attributed to the growth of the market is the rising prevalence of atopic dermatitis across the globe. As per the information provided by the National Eczema Association which highlighted the fact that around 9.6 million US children under the age of 18 have atopic dermatitis, along with one-third have moderate to severe diseases, and childhood atopic dermatitis has steadily increased from 8% to 12% since 1997. Moreover, the major players in the industry are going on with research and development activities to bring up new products in the market for the treatment of atopic dermatitis. The mergers between the companies for the development of these products are supporting the market to grow further.
Browse the full report of "Global High-Affinity Nerve Growth Factor Receptor Market Size, Share, and Trends Analysis Report By Drug Type (ASP-7962, AZD-7451, BNN-27, Cenegermin, CRB-0089, and Others) and By Application (Atopic Dermatitis, Cancer, and Others) Forecast 2022-2028" at https://www.omrglobal.com/industry-reports/high-affinity-nerve-growth-factor-receptor-market
For instance, in February 2022, Akeso, Inc. announced that the clinical trial application of the innovative nerve growth factor (NGF) monoclonal antibody injection developed in-house by the Company, has obtained approval from the Centre for Drug Evaluation of China's National Medical Products Administration to begin a clinical trial for the treatment of pain (including cancer pain).
Further, in June 2021, Amgen Inc. and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape - including, GlaxoSmithKline PLC, Sanofi SA, Merck & Co. inc., Pfizer Inc., Novartis International AG, among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global High-Affinity Nerve Growth Factor Receptor Market Report Segment
By Drug Type
By Application
Global High Affinity Nerve Growth Factor Receptor Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World